Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
No open-market purchases or sales by Faeth Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Faeth Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 20 | 10 | −10 |
| SharesConverted for a 1-for-20 split | 96.5K | 69.9K | −26.5K (−27.5%) |
| Value | $760.2K | $600.0K | −$160.2K (−21.1%) |
New holders (0)
Institutions that held Faeth Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
None.
Sold out (10)
Institutions that held Faeth Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Renaissance Technologies LLC | 177,300 | $69.9K |
| Geode Capital Management, LLC | 150,709 | $59.4K |
| Boothbay Fund Management, LLC | 108,658 | $42.8K |
| Northern Trust Corp | 25,983 | $10.2K |
| State Street Corp | 25,774 | $10.2K |
| Cresset Asset Management, LLC | 19,671 | $7.75K |
| NWF Advisory Services Inc. | 16,514 | $6.51K |
| Tower Research Capital LLC (TRC) | 5,404 | $2.13K |
| Barclays PLC | 2,558 | $1.01K |
| Citigroup Inc | 124 | $49 |